My PCR
Create Account
Logo PCR

22 May 2025

Antiplatelet strategies for patients undergoing PCI

Facilitators: A. Greco, K. Kozuma
Speakers: O. Angerås, A. Aksoy, H. S. Jeon, G. Sánchez-Elvira, A. Landi

Summary

Delve into this comprehensive session focusing on antiplatelet strategies for patients undergoing PCI. Explore evidence and clinical insights on ticagrelor monotherapy post-AMI stenting, shortened dual antiplatelet therapy (DAPT) durations, the role of CYP2C19 genotyping in stent thrombosis risk, the effectiveness of dual antithrombotic therapy in atrial fibrillation patients, and antiplatelet management in high bleeding risk patients with chronic kidney disease.

Presentations available when logged in:

  • Ticagrelor monotherapy after coronary stenting in patients with AMI
  • Propensity-score-matched study of a shortened DAPT duration
  • A mechanistic framework using CYP2C19 genotype, phenotype, and clinical factors for stent thrombosis
  • Is dual antithrombotic therapy effective after PCI in atrial fibrillation? - A real-world registry
  • Antiplatelet therapy after PCI in high bleeding risk patients with chronic kidney disease